These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

435 related items for PubMed ID: 19531531

  • 1. CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system.
    Mildner A, Mack M, Schmidt H, Brück W, Djukic M, Zabel MD, Hille A, Priller J, Prinz M.
    Brain; 2009 Sep; 132(Pt 9):2487-500. PubMed ID: 19531531
    [Abstract] [Full Text] [Related]

  • 2. Licensing of myeloid cells promotes central nervous system autoimmunity and is controlled by peroxisome proliferator-activated receptor γ.
    Hucke S, Floßdorf J, Grützke B, Dunay IR, Frenzel K, Jungverdorben J, Linnartz B, Mack M, Peitz M, Brüstle O, Kurts C, Klockgether T, Neumann H, Prinz M, Wiendl H, Knolle P, Klotz L.
    Brain; 2012 May; 135(Pt 5):1586-605. PubMed ID: 22447120
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2.
    Serbina NV, Pamer EG.
    Nat Immunol; 2006 Mar; 7(3):311-7. PubMed ID: 16462739
    [Abstract] [Full Text] [Related]

  • 5. CCR2-dependent dendritic cell accumulation in the central nervous system during early effector experimental autoimmune encephalomyelitis is essential for effector T cell restimulation in situ and disease progression.
    Clarkson BD, Walker A, Harris MG, Rayasam A, Sandor M, Fabry Z.
    J Immunol; 2015 Jan 15; 194(2):531-41. PubMed ID: 25505278
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacological profile of JNJ-27141491 [(S)-3-[3,4-difluorophenyl)-propyl]-5-isoxazol-5-yl-2-thioxo-2,3-dihydro-1H-imidazole-4-carboxyl acid methyl ester], as a noncompetitive and orally active antagonist of the human chemokine receptor CCR2.
    Buntinx M, Hermans B, Goossens J, Moechars D, Gilissen RA, Doyon J, Boeckx S, Coesemans E, Van Lommen G, Van Wauwe JP.
    J Pharmacol Exp Ther; 2008 Oct 15; 327(1):1-9. PubMed ID: 18599682
    [Abstract] [Full Text] [Related]

  • 9. CCL2, but not its receptor, is essential to restrict immune privileged central nervous system-invasion of Japanese encephalitis virus via regulating accumulation of CD11b(+) Ly-6C(hi) monocytes.
    Kim JH, Patil AM, Choi JY, Kim SB, Uyangaa E, Hossain FM, Park SY, Lee JH, Kim K, Eo SK.
    Immunology; 2016 Oct 15; 149(2):186-203. PubMed ID: 27260136
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Bone marrow-derived mast cells accumulate in the central nervous system during inflammation but are dispensable for experimental autoimmune encephalomyelitis pathogenesis.
    Bennett JL, Blanchet MR, Zhao L, Zbytnuik L, Antignano F, Gold M, Kubes P, McNagny KM.
    J Immunol; 2009 May 01; 182(9):5507-14. PubMed ID: 19380799
    [Abstract] [Full Text] [Related]

  • 13. 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking.
    Pedersen LB, Nashold FE, Spach KM, Hayes CE.
    J Neurosci Res; 2007 Aug 15; 85(11):2480-90. PubMed ID: 17600374
    [Abstract] [Full Text] [Related]

  • 14. Selective inhibition of CCR2 expressing lymphomyeloid cells in experimental autoimmune encephalomyelitis by a GM-CSF-MCP1 fusokine.
    Rafei M, Campeau PM, Wu JH, Birman E, Forner K, Boivin MN, Galipeau J.
    J Immunol; 2009 Mar 01; 182(5):2620-7. PubMed ID: 19234156
    [Abstract] [Full Text] [Related]

  • 15. TNFR1-dependent VCAM-1 expression by astrocytes exposes the CNS to destructive inflammation.
    Gimenez MA, Sim JE, Russell JH.
    J Neuroimmunol; 2004 Jun 01; 151(1-2):116-25. PubMed ID: 15145610
    [Abstract] [Full Text] [Related]

  • 16. Ly-6G+CCR2- myeloid cells rather than Ly-6ChighCCR2+ monocytes are required for the control of bacterial infection in the central nervous system.
    Mildner A, Djukic M, Garbe D, Wellmer A, Kuziel WA, Mack M, Nau R, Prinz M.
    J Immunol; 2008 Aug 15; 181(4):2713-22. PubMed ID: 18684962
    [Abstract] [Full Text] [Related]

  • 17. Differential contribution of immune effector mechanisms to cortical demyelination in multiple sclerosis.
    Lagumersindez-Denis N, Wrzos C, Mack M, Winkler A, van der Meer F, Reinert MC, Hollasch H, Flach A, Brühl H, Cullen E, Schlumbohm C, Fuchs E, Linington C, Barrantes-Freer A, Metz I, Wegner C, Liebetanz D, Prinz M, Brück W, Stadelmann C, Nessler S.
    Acta Neuropathol; 2017 Jul 15; 134(1):15-34. PubMed ID: 28386765
    [Abstract] [Full Text] [Related]

  • 18. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions.
    Mildner A, Schmidt H, Nitsche M, Merkler D, Hanisch UK, Mack M, Heikenwalder M, Brück W, Priller J, Prinz M.
    Nat Neurosci; 2007 Dec 15; 10(12):1544-53. PubMed ID: 18026096
    [Abstract] [Full Text] [Related]

  • 19. Encephalitogenic lymphoblast recruitment to resting CNS microvasculature: a natural immunosurveillance mechanism?
    Alon R.
    J Clin Invest; 2001 Aug 15; 108(4):517-9. PubMed ID: 11518723
    [No Abstract] [Full Text] [Related]

  • 20. Myelin proteolipid protein: an effective autoantigen and target of autoimmunity in multiple sclerosis.
    Greer JM, Pender MP.
    J Autoimmun; 2008 Nov 15; 31(3):281-7. PubMed ID: 18502611
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.